R&D Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–12 of 73 articles
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
Eli Lilly raises 2026 revenue guidance on Mounjaro demand
Eli Lilly Retatrutide Phase 3: Safety Data and Competitive Implications
Lundbeck Advances Lu AG09222 After Phase 2 Migraine Data
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Celcuity Expands VIKTORIA-2 Trial as Shares Trade Below Analyst Targets
FDA Flavored Vape Ban: Youth Risk and Pharma Implications
Opinion: I led the CDC response to the 2014 Ebola epidemic. The new outbreak needs massive
Amish Health Beliefs: Vaccines, Costs, and Pharma Strategy Insights
STAT+: What stripping civil service protections for thousands of federal workers will mean for HHS
OHRP Underfunding Risks Human Subject Protection in 2026